IRIS
DE LUCA, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 26.903
EU - Europa 21.193
AS - Asia 9.397
SA - Sud America 1.824
Continente sconosciuto - Info sul continente non disponibili 925
AF - Africa 542
OC - Oceania 53
Totale 60.837
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 26.565
GB - Regno Unito 5.852
IT - Italia 3.902
CN - Cina 3.103
RU - Federazione Russa 2.947
SG - Singapore 2.850
IE - Irlanda 2.460
UA - Ucraina 1.867
BR - Brasile 1.526
FR - Francia 1.191
VN - Vietnam 1.104
DE - Germania 966
HK - Hong Kong 924
SE - Svezia 870
FI - Finlandia 519
IN - India 237
BD - Bangladesh 234
ZA - Sudafrica 229
KR - Corea 203
CA - Canada 176
NG - Nigeria 134
NL - Olanda 133
ES - Italia 116
TR - Turchia 107
AR - Argentina 100
IQ - Iraq 96
MX - Messico 84
PK - Pakistan 72
AT - Austria 67
BE - Belgio 61
PL - Polonia 61
JP - Giappone 57
ID - Indonesia 46
VE - Venezuela 44
CO - Colombia 42
IR - Iran 42
AU - Australia 40
PH - Filippine 40
EC - Ecuador 38
SA - Arabia Saudita 34
KE - Kenya 31
MA - Marocco 30
UZ - Uzbekistan 29
MY - Malesia 28
CL - Cile 27
CZ - Repubblica Ceca 27
JO - Giordania 23
AE - Emirati Arabi Uniti 21
KZ - Kazakistan 18
NP - Nepal 17
PY - Paraguay 17
EG - Egitto 16
EU - Europa 16
GR - Grecia 16
PT - Portogallo 16
IL - Israele 15
CH - Svizzera 14
TN - Tunisia 14
DZ - Algeria 13
ET - Etiopia 13
JM - Giamaica 13
LT - Lituania 13
PE - Perù 13
LB - Libano 12
AL - Albania 11
AZ - Azerbaigian 11
CI - Costa d'Avorio 11
UG - Uganda 11
UY - Uruguay 11
BG - Bulgaria 10
CR - Costa Rica 10
OM - Oman 10
PA - Panama 10
TH - Thailandia 10
NZ - Nuova Zelanda 9
SK - Slovacchia (Repubblica Slovacca) 9
HN - Honduras 8
HU - Ungheria 8
PS - Palestinian Territory 8
SN - Senegal 8
DO - Repubblica Dominicana 7
KG - Kirghizistan 7
LV - Lettonia 7
TT - Trinidad e Tobago 7
AO - Angola 6
DK - Danimarca 6
LU - Lussemburgo 6
TW - Taiwan 6
EE - Estonia 5
LK - Sri Lanka 5
NO - Norvegia 5
RS - Serbia 5
AM - Armenia 4
BA - Bosnia-Erzegovina 4
BO - Bolivia 4
BS - Bahamas 4
BW - Botswana 4
BY - Bielorussia 4
GA - Gabon 4
GH - Ghana 4
Totale 59.850
Salva come PNG Salva come JPEG
Città #
Southend 5.243
Fairfield 2.919
Dallas 2.653
Dublin 2.442
Ashburn 1.957
Chandler 1.789
Jacksonville 1.529
Woodbridge 1.471
Singapore 1.388
Seattle 1.160
Wilmington 1.143
Cambridge 1.024
Houston 1.016
Hong Kong 877
Milan 816
Moscow 722
Santa Clara 713
San Jose 709
Council Bluffs 696
Beijing 670
Ann Arbor 645
Munich 494
Princeton 493
The Dalles 489
Nanjing 455
Menlo Park 453
Siena 422
Rome 374
Helsinki 372
Los Angeles 307
Lauterbourg 301
Boardman 277
Ho Chi Minh City 267
Hanoi 247
New York 239
Dong Ket 229
Seoul 197
Hefei 196
Johannesburg 181
San Diego 160
Nanchang 146
Buffalo 139
Shenyang 135
São Paulo 131
Columbus 125
Abuja 121
Redondo Beach 120
Dearborn 114
Turin 99
Tianjin 98
Changsha 89
London 88
Hebei 84
Figino 83
Bologna 78
Shanghai 78
San Mateo 71
Jiaxing 68
Nuremberg 66
Orem 64
Málaga 61
Florence 59
Frankfurt am Main 59
Toronto 59
Naples 55
Brussels 53
Chennai 53
Chicago 52
Kunming 52
Zhengzhou 51
Jinan 50
San Francisco 47
Tokyo 47
Guangzhou 46
Norwalk 46
Phoenix 46
Ningbo 45
Izmir 42
Belo Horizonte 41
Turku 41
Vienna 40
Warsaw 40
Da Nang 39
Düsseldorf 39
Brooklyn 38
Rio de Janeiro 38
Baghdad 36
Genoa 36
Haiphong 36
Montreal 36
Taizhou 35
Atlanta 34
Lancaster 33
Dhaka 30
Falls Church 30
Stockholm 28
Tashkent 27
Nairobi 26
Hangzhou 25
Lahore 25
Totale 41.408
Salva come PNG Salva come JPEG
Nome #
Utilizzo di dalbavancina nella terapia delle infezioni osteoarticolari 1.443
Accumulation of HIV-1 drug resistance in patients on a standard thymidine analogue-based first line antiretroviral therapy after virological failure: Implications for the activity of next-line regimens from a longitudinal study in Mozambique 663
A Prognostic Model for Estimating the Time to Virologic Failure in HIV-1 Infected Patients Undergoing a New Combination Antiretroviral Therapy Regimen 635
Staphylococcus aureus vaccine preclinical and clinical development: current state of the art 587
UTILIZZO DI MILTEFOSINA IN PAZIENTE CON LEISHMANIOSI MUCOSA ED INFEZIONE DA HIV 580
"EFFICACY AND SAFETY OF 2-DRUG COMBINATION ANTIRETROVIRAL THERAPY IN CLINICAL PRACTICE: RESULTS FROM A SINGLE CENTER STUDY" 575
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus 504
Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study 399
AIDS-associated cerebral toxoplasmosis: an update on diagnosis and treatment. 385
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: A pilot, prospective controlled study 369
Listeria meningoencephalitis and anti-GQ1b antibody syndrome 352
An outbreak of HIV-1 subtype G among Italian injecting drug users 348
ERITEMA NODOSO RECIDIVANTE E PERSISTENTE REPLICA DI EPSTEIN-BARR VIRUS 342
Non-granulomatous cerebellar infection by Acanthamoeba spp. in an immunocompetent host 330
Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe 316
A novel methodology for large-scale phylogeny partition 309
Analisi retrospettiva su infezioni invasive e non invasive da batteri Gram negativi non fermentanti in pazienti ospedalizzati 308
Impact of transmitted HIV-1 drug resistance on the efficacy of first-line antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor 306
Nuovi approci diagnostici nelle infezioni pneumococciche: possibile ruolo della Real-time PCR e dei biomarcatori 306
Maraviroc as a potential HIV-1 latency-reversing agent in cell line models and ex vivo CD4 T cells 303
Impact of transmitted drug resistance in naïve-patients starting 2 NRTI plus a boosted protease-inhibitor (PI) or integrase-inhibitor (INSTI). 302
Predicting 2-drug antiretroviral regimen efficacy by genotypic susceptibility score: results from a cohort study 302
Paediatric obstructive sleep apnoea syndrome (OSAS) is associated with tonsil colonisation by Streptococcus pyogenes 297
Case Report: Persistent strongyloidiasis complicated by recurrent meningitis in an HTLV seropositive Peruvian migrant resettled in Italy 291
HCMV infection in renal transplant recipients: a retrospective cohort study 290
Impact of the M184V resistance mutation on virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals with suppressed HIV-1 RNA: A cohort study 290
Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort 289
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 286
Evaluation and Optimization of an ELISA Procedure to Quantify Antibodies Against Pneumococcal Polysaccharides Included in the 13-Valent Conjugate Vaccine 283
Strategie di vaccinazione anti-pneumococcica nel paziente adulto HIV-positivo: confronto fra vaccino coniugato 13-valente e vaccino polisaccaridico 23-valente 282
Evolution of macrolide resistance in streptococcus pyogenes over 14 years in an area of central Italy 281
Analysis of genetic and viral determinants of HBsAg levels in patients with chronic HBV infection 281
Clinical and MRI improvement in a case of progressive multifocal leukoencephalopathy 279
First report of spondylodiscitis due to vancomycin heteroresistant Staphylococcus capitis in immunocompetent host 279
Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort 278
Sieroprevalenza di HEV in donatori di sangue e pazienti trapiantati di rene nella provincia di Siena. 273
Virological and Immunological Response to Antiretroviral Regimens Containing Maraviroc in HIV Type 1-Infected Patients in Clinical Practice: Role of Different Tropism Testing Results and of Concomitant Treatments 270
Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA 270
Seroprevalence of hepatitis E virus (HEV) infection in blood donors and renal transplant recipients: a retrospective study from central Italy [Sieroprevalenza dell’infezione da virus dell’epatite E (HEV) in donatori di sangue e pazienti trapiantati di rene: Uno studio retrospettivo dal centro Italia] 269
Pediatric spinal epidural abscess in an immunocompetent host without risk factors: Case report and review of the literature 268
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial 263
Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score 262
Natural NS5A inhibitor resistance associated substitutions in hepatitis C virus genotype 1 infected patients from Italy 259
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy 251
HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART 250
Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility 249
FIBRILLO-FLUTTER IN ASSENZA DI SEGNI DI MIOCARDITE IN CORSO DI INFEZIONE DA EBV 243
Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. 243
A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study 243
Un caso di “insolita” spondilodiscite da Staphylococcus capitis 243
Impact of resistance mutations on virological efficacy of DTG-based maintenance two-drug regimens: a cohort study 243
Current and emerging two-drug approaches for HIV-1 therapy in ART-naïve and ART-experienced, virologically suppressed patients 238
Risposta immunitaria a lungo termine dopo vaccinazione antipneumococcica con vaccino coniugato 13-valente o vaccino polisaccaridico 23-valente in adulti HIV positivi 237
Predicting 2-drug antiretroviral regimen efficacy by genotypic susceptibility score: results from a cohort study 237
Diagnosi di sarcoidosi in nuova diagnosi di HIV 233
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016 232
Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors 231
Prevalence, incidence and predictors of anal high-risk HPV infections and cytological abnormalities in HIV-infected individuals 224
High burden of transmitted HIV-1 drug resistance in Italian patients carrying F1 subtype 221
A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loads 220
233. Diagnosis of AIDS-related focal brain lesions: a decision-making analysis based on clinical and neuroradiologic characteristics combined with polymerase chain reaction assays in CSF. 219
Impact of resistance mutations on virological efficacy of DTG-based maintenance two-drug regimens: an ARCA cohort study 219
Kaposi Sarcoma Incidence and Survival Among HIV-Infected Homosexual Men After HIV Seroconversion 218
Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre 218
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study 218
Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA 218
PATOGENI COLONIZZANTI IL NASOFARINGE DI SOGGETTI HIV POSITIVI E HIV NEGATIVI 217
Cytomegalovirus Coinfection Is Associated With an Increased Risk of Severe Non-AIDS-Defining Events in a Large Cohort of HIV-Infected Patients 217
Letter to the editor: switching treatment to lamivudine plus boosted atazanavir or darunavir in virologically suppressed HIV-infected patients – evidence from a large observational cohort 217
Prevalence of M75 Streptococcus Pyogenes strains harboring slaa gene in patients affected by pediatric obstructive sleep apnea syndrome in Central Italy 217
MIASI CAVITARIA A LOCALIZZAZIONE NASALE DA OESTRUS OVIS: UN CASO CLINICO 215
Distribution of different HBV DNA forms in plasma and peripheral blood mononuclear cells (PBMCs) of chronically infected patients with low or undetectable HBV plasma viremia 215
Un raro caso di osteomielite da Moraxella osloensis e Staphylococcus capitis in giovane paziente immunocompetente 214
Valutazione della risposta al test IGRA in pazienti pediatrici contatto di TBC o con sospetto clinico di infezione attiva 213
European guidelines on the clinical management of HIV-1 tropism testing 213
Evoluzione ed efficace controllo di un vasto focolaio epidemico nosocomiale da Klebsiella pneumoniae produttrice di carbapenemasi in un’area Neurochirurgica: lezioni apprese. 211
Compartimentalizzazione di HCMV: mancata appropiatezza della sola DNAemia nella diagnosi e nella terapia di una polmonite da HCMV post-trapianto polmonare 210
Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCR. 207
Dynamics of total and intact HIV-1 DNA in virologically suppressed patients switching to DTG- or ATV-based dual therapy 205
Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load 202
Clinical evaluation of Rega 8: an updated genotypic interpretation system that significantly predicts HIV-therapy response 200
La diagnosi eziologica della polmonite comunitaria: possibile ruolo della Real-Time PCR in una coorte di pazienti adulti e pediatrici 200
Gastroenteritis and Intractable Diarrhea in Newborns 200
Meningite purulenta a decorso atipico in età pediatrica 199
An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project 198
LA MALATTIA PNEUMOCOCCICA IN ETÀ PEDIATRICA: CONFRONTO FRA EPOCA PRE- E POST-VACCINALE 198
Impact of NRTI resistance mutations on virological effectiveness of antiretroviral regimens containing elvitegravir: A multi-cohort study 196
Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007-2009 194
A whole-genome association study of major determinants for host control of HIV-1 RID A-6681-2009 RID A-2073-2010 RID B-5656-2009 RID F-2587-2010 RID G-8810-2011 192
Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort 192
Alveolar macrophages from AIDS patients spontaneously produce elevated levels of TNF-alpha in vitro. 189
"Buffalo hump" in HIV-1 infection RID G-8810-2011 188
Long-term immune response to 13-valent Pneumococcal Conjugate Vaccine versus 23-valent Polysaccharide Vaccine in HIV-1 infected adults 187
Mitochondrial DNA haplogroups and incidence of lipodystrophy in HIV-infected patients on long-term antiretroviral therapy 187
The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study 187
AIDS-related focal brain lesions in the era of highly active antiretroviral therapy RID G-8810-2011 RID A-1577-2008 186
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL 186
Association study of common genetic variants and HIV-1 acquisition in 6,300 infected cases and 7,200 controls 186
Tubercolosi e "pregiudizio epidemiologico": diagnosi invasiva di sarcoidosi necrotizzante in giovane immigrato 185
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients 183
Totale 27.958
Salva come PNG Salva come JPEG
Categoria #
all - tutte 186.372
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 186.372
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20223.386 0 477 143 282 137 167 169 184 213 432 348 834
2022/20235.735 371 308 592 893 675 1.267 76 463 625 136 170 159
2023/20243.659 197 120 282 146 149 865 1.209 119 27 111 144 290
2024/20257.635 230 493 589 422 676 439 450 608 775 339 783 1.831
2025/202616.236 1.193 2.224 1.733 1.404 2.876 748 2.150 550 543 839 469 1.507
2026/20271.202 700 502 0 0 0 0 0 0 0 0 0 0
Totale 60.837